Clinical trials for the treatment of Coronavirus disease 2019 (COVID-19): A rapid response to urgent need

Science China Life Sciences

Volumn 63, Issue 5, 2020, Pages 774-776

  Zhang, Tengyue ^a   He, Yudi ^a   Xu, Wenshuai ^a   Ma, Aiping ^b   Yang, Yanli ^a   Xu, Kai Feng ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETACORONAVIRUS; CLINICAL TRIAL (TOPIC); CORONAVIRUS DISEASE 2019; CORONAVIRUS INFECTION; HUMAN; PANDEMIC; VIRUS PNEUMONIA;

BETACORONAVIRUS; CLINICAL TRIALS AS TOPIC; CORONAVIRUS INFECTIONS; HUMANS; PANDEMICS; PNEUMONIA, VIRAL;

EID: 85081610362     PISSN: 16747305     EISSN: 18691889     Source Type: Journal    
DOI: 10.1007/s11427-020-1660-2     Document Type: Article

References (5)

1. Chan, K.S., Lai, S.T., Chu, C.M., Tsui, E., Tarn, C.Y., Wong, M.M., Tse, M. W., Que, T.L., Peiris, J.S., Sung, J., et al. (2003). Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J 9, 399–406.
2. Chen, Y., Guo, J.J., Healy, D.P., and Zhan, S. (2007). Effect of integrated traditional Chinese medicine and western medicine on the treatment of severe acute respiratory syndrome: A meta-analysis. Pharmacy pract (Granada Ed impr) 5, 1–9.
3. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020). Clinical features of patients infected with 2019 novel Coronavirus in Wuhan, China. Lancet 395, 497–506.
4. Maxmen, A. (2020). More than 80 clinical trials launch to test Coronavirus treatments. Nature 578, 347–348.
5. Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., and Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel Coronavirus (2019-nCoV) in vitro. Cell Res doi: 10.1038/s41422-020-0282-0.